Patent application number | Description | Published |
20080227663 | SYSTEMS AND METHODS FOR HIGH SPEED ARRAY PRINTING AND HYBRIDIZATION - Novel and improved systems and methods for high speed arraying, hybridization, quantitative development and/or assaying are provided. Some embodiments provide a web based arraying format. Some other embodiments provide a sheet based arraying format. Some embodiments use a drop on drop assaying or hybridization mode. In some embodiments, a substantially inert substrate is utilized. In some other embodiments, an interactive substrate is utilized. | 09-18-2008 |
20090055100 | METHOD FOR IDENTIFYING AND/OR CHARACTERIZING A (POLY)PEPTIDE - The present invention relates to a method for identifying and/or characterizing a (poly)peptide comprising: (a) analyzing a peptide map of said (poly)peptide, comprising at least 1 peptide, and its peptide primary structure fingerprint by mass spectrometry; and (b) comparing data obtained in step (a) with a reference (poly)peptide database, said database comprising mass spectrometric data of peptide maps, comprising at least 1 peptide, and of its peptide primary structure fingerprint, of a (poly)peptide or of a variety of (poly)peptides. | 02-26-2009 |
20090060793 | MICRODISPENSER AND ASSOCIATED OPERATING METHOD - The invention relates to a microdispenser ( | 03-05-2009 |
20120101008 | Method And Devices For Depositing Samples On An Electrically Shielded Substrat - A method for depositing samples, in which at least one sample ( | 04-26-2012 |
20120312836 | MICRODISPENSER AND ASSOCIATED OPERATING METHOD - The invention relates to a microdispenser ( | 12-13-2012 |
20130150266 | SYSTEMS AND METHODS FOR HIGH SPEED ARRAY PRINTING AND HYBRIDIZATION - Novel and improved systems and methods for high speed arraying, hybridization, quantitative development and/or assaying are provided. Some embodiments provide a web based arraying format. Some other embodiments provide a sheet based arraying format. Some embodiments use a drop on drop assaying or hybridization mode. In some embodiments, a substantially inert substrate is utilized. In some other embodiments, an interactive substrate is utilized. | 06-13-2013 |
20130237443 | SPOTTING PLATE AND PROCESS FOR ITS PRODUCTION - A process for the production of a reaction chamber assembly, wherein a flat substrate and bottomless reaction chambers are provided, the substrate is first loaded with a biological agent and then the bottomless reaction chambers are bonded glue-free to the substrate, in particular through laser bonding, and liquid-tight reaction chambers, for instance individual wells, individually connected wells, such as strips, or wells in the form of a microtiter plate, are obtained. The present invention further provides a kit comprising a substrate suitable for being loaded with at least one biological agent and at least one bottomless reaction chamber, wherein the kit is suitable for glue-free bonding of the bottomless reaction chamber to the substrate. | 09-12-2013 |
20150119296 | SYSTEMS AND METHODS FOR HIGH SPEED ARRAY PRINTING AND HYBRIDIZATION - Novel and improved systems and methods for high speed arraying, hybridization, quantitative development and/or assaying are provided. Some embodiments provide a web based arraying format. Some other embodiments provide a sheet based arraying format. Some embodiments use a drop on drop assaying or hybridization mode. In some embodiments, a substantially inert substrate is utilized. In some other embodiments, an interactive substrate is utilized. | 04-30-2015 |
Patent application number | Description | Published |
20130079345 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES - The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase. | 03-28-2013 |
20140018365 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS - The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof. | 01-16-2014 |
20140179662 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES - The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase. | 06-26-2014 |
20140287454 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS - The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to a selective CDK9 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with a selective CDK9 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to a selective CDK9 inhibitor, whereby the patient is suspected to suffer from NUT midline carcinoma (NMC). The present invention also relates to a method of monitoring or predicting the efficacy of a treatment of NUT midline carcinoma (NMC), wherein treatment with a selective CDK9 inhibitor is in particular envisaged. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one rearrangement in the NUT gene for screening and/or validation of a medicament for the treatment NUT midline carcinoma (NMC) is described. Furthermore, a kit useful for carrying out the methods described herein as well as an oligo- or polynucleotide capable of detecting rearrangements in the NUT gene are provided. | 09-25-2014 |
20140296304 | Pharmaceutically Active Disubstituted Pyridine Derivatives - The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase. | 10-02-2014 |
20140303167 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA - The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention. | 10-09-2014 |
20150018329 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES - The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase. | 01-15-2015 |
20150111873 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES - Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase. | 04-23-2015 |
20150329537 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA - The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention. | 11-19-2015 |
Patent application number | Description | Published |
20090292415 | Method and apparatus for detecting a circuit failure in a vehicle brake system - In a vehicle brake system including first and second brake circuits, a dual-circuit brake actuator, first and second control lines, the first brake circuit including a first brake pressure regulating valve and a first pressure sensor, the second brake circuit including a second brake pressure regulating valve and a second pressure sensor, the brake actuator connected to the first valve via the first control line to control that valve, and, via the second control line, to the second valve to control that valve, a control unit is communicatively connected to the pressure sensors and brake actuator and is adapted to effect a method for detecting a brake system circuit failure including determining a first pressure difference in the first brake circuit and a second pressure difference in the second brake circuit during actuation of the brake actuator, and determining a first comparison value from the first and second pressure differences. | 11-26-2009 |
20140232178 | Braking Method and Braking Device for a Vehicle and Hydraulic Brake System and Vehicle Associated Therewith - A braking device for a vehicle, comprises a main brake cylinder, which provides, in response to the actuation thereof, an operating brake pressure in at least one operating brake circuit for the actuation of an operating brake A hydraulic fluid pressure intake connected to a hydraulic circuit, which contains a hydraulic fluid having a built-up hydraulic circuit pressure. Through the hydraulic fluid pressure intake, the hydraulic fluid is provided at the hydraulic circuit pressure. The braking device further comprises a valve device, which actively controls a main brake cylinder actuation pressure and/or a parking brake release pressure by means of the hydraulic fluid that is provided. The main brake cylinder is actuated by means of the main brake cylinder actuation pressure for an active brake engagement. Alternatively or additionally, a parking brake is hydraulically released by means of the parking brake release pressure. | 08-21-2014 |
20140306515 | VEHICLE BRAKING UNIT AND METHOD - A vehicle braking unit comprises an operating braking pressure inlet which receives an inlet braking pressure built up by a braking cylinder, and at least one operating brake pressure outlet at which an outlet braking pressure is provided for an operating brake modulator, which is upstream of the operating brake and provides anti-lock functionality. At least one connecting channel hydraulically connects the operating brake pressure inlet to the outlet. Brake fluid is supplied from a storage unit through the brake cylinder, the connecting channel and the operating brake modulator. The braking unit has a brake fluid inlet, through which the brake fluid is received from the storage unit, a brake fluid pump, by which the brake fluid is suctioned through the brake fluid inlet and a supply pressure is built up, and a valve unit that controls the outlet braking pressure and/or a parking brake release pressure by the supply pressure. | 10-16-2014 |